Eslam, MohammedNewsome, Philip NSarin, Shiv KAnstee, Quentin MTargher, GiovanniRomero-Gomez, ManuelZelber-Sagi, ShiraWai-Sun Wong, VincentDufour, Jean-FrançoisSchattenberg, Jörn MKawaguchi, TakumiArrese, MarcoValenti, LucaShiha, GamalTiribelli, ClaudioYki-Järvinen, HanneleFan, Jian-GaoGrønbæk, HenningYilmaz, YusufCortez-Pinto, HelenaOliveira, Claudia PBedossa, PierreAdams, Leon AMing-Hua, ZhengFouad, YasserWah-Kheong, ChanMendez-Sanchez, NahumSang Hoon, AhnCastera, LaurentBugianesi, ElisabettaRatziu, VladGeorge, Jacob2023-02-082023-02-082020-04-08Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209.http://hdl.handle.net/10668/15358The exclusion of other chronic liver diseases including "excess" alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, "positive criteria" to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.enCirrhosisDiabetesDiagnostic criteriaMAFLDMetabolicNAFLDObesitySteatohepatitisCausalityConsensusDiabetes Mellitus, Type 2Disease ProgressionFatty LiverHumansLiver CirrhosisMetabolic DiseasesObesityTerminology as Topicresearch article32278004Restricted AccessHígado grasoDiagnósticoHepatopatíasPatogénesis homeopáticaIlegitimidadCodificación clínicaConsumo de bebidas alcohólicasSobrepesoObesidadDiabetes Mellitus Tipo 210.1016/j.jhep.2020.03.0391600-0641http://www.journal-of-hepatology.eu/article/S0168827820302014/pdf